Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer

J. R. Kroep; E. F. Smit; G. Giaccone; K. Van Der Born; J. H. Beijnen; C. J. Van Groeningen; W. J F Van Der Vijgh; P. E. Postmus; H. M. Pinedo; G. J. Peters

doi:10.1007/s00280-006-0191-z

Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer

J. R. Kroep, E. F. Smit, G. Giaccone, K. Van Der Born, J. H. Beijnen, C. J. Van Groeningen, W. J F Van Der Vijgh, P. E. Postmus, H. M. Pinedo, G. J. Peters

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Purpose: To compare the pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer (NSCLC). Patients and methods: Twenty-four chemo-naive patients with advanced NSCLC were randomized to receive one of the three regimens. Plasma pharmacokinetics and pharmacologic parameters in mononuclear cells were compared and related to toxicity and efficacy. Results: Pharmacological parameters of gemcitabine and cisplatin were not influenced by the combination with one of the other agents, while the paclitaxel clearance was significantly lower for the combination with cisplatin as compared to gemcitabine (P=0.024). The percentage decrease in platelets was significantly higher for the gemcitabine combinations (P=0.004) and related to the dFdCTP-C_max (P=0.030). Pharmacologic parameters were not related to response or survival. Conclusions: Gemcitabine and cisplatin pharmacology were not influenced by the combination with one of the other agents, while paclitaxel has a lower clearance in combination with cisplatin as compared to gemcitabine.

Original language	English (US)
Pages (from-to)	509-516
Number of pages	8
Journal	Cancer Chemotherapy and Pharmacology
Volume	58
Issue number	4
DOIs	https://doi.org/10.1007/s00280-006-0191-z
State	Published - Oct 2006
Externally published	Yes

Keywords

Cisplatin
Gemcitabine
Non-small cell lung cancer
Paclitaxel

ASJC Scopus subject areas

Cancer Research
Pharmacology
Oncology

Access to Document

10.1007/s00280-006-0191-z

Cite this

Kroep, J. R., Smit, E. F., Giaccone, G., Van Der Born, K., Beijnen, J. H., Van Groeningen, C. J., Van Der Vijgh, W. J. F., Postmus, P. E., Pinedo, H. M., & Peters, G. J. (2006). Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 58(4), 509-516. https://doi.org/10.1007/s00280-006-0191-z

Kroep, JR, Smit, EF, Giaccone, G, Van Der Born, K, Beijnen, JH, Van Groeningen, CJ, Van Der Vijgh, WJF, Postmus, PE, Pinedo, HM & Peters, GJ 2006, 'Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer', Cancer Chemotherapy and Pharmacology, vol. 58, no. 4, pp. 509-516. https://doi.org/10.1007/s00280-006-0191-z

@article{fe2a5cc1252d48f98bc978c2b0e2e3e4,

title = "Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer",

abstract = "Purpose: To compare the pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer (NSCLC). Patients and methods: Twenty-four chemo-naive patients with advanced NSCLC were randomized to receive one of the three regimens. Plasma pharmacokinetics and pharmacologic parameters in mononuclear cells were compared and related to toxicity and efficacy. Results: Pharmacological parameters of gemcitabine and cisplatin were not influenced by the combination with one of the other agents, while the paclitaxel clearance was significantly lower for the combination with cisplatin as compared to gemcitabine (P=0.024). The percentage decrease in platelets was significantly higher for the gemcitabine combinations (P=0.004) and related to the dFdCTP-Cmax (P=0.030). Pharmacologic parameters were not related to response or survival. Conclusions: Gemcitabine and cisplatin pharmacology were not influenced by the combination with one of the other agents, while paclitaxel has a lower clearance in combination with cisplatin as compared to gemcitabine.",

keywords = "Cisplatin, Gemcitabine, Non-small cell lung cancer, Paclitaxel",

author = "Kroep, {J. R.} and Smit, {E. F.} and G. Giaccone and {Van Der Born}, K. and Beijnen, {J. H.} and {Van Groeningen}, {C. J.} and {Van Der Vijgh}, {W. J F} and Postmus, {P. E.} and Pinedo, {H. M.} and Peters, {G. J.}",

year = "2006",

month = oct,

doi = "10.1007/s00280-006-0191-z",

language = "English (US)",

volume = "58",

pages = "509--516",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer

AU - Kroep, J. R.

AU - Smit, E. F.

AU - Giaccone, G.

AU - Van Der Born, K.

AU - Beijnen, J. H.

AU - Van Groeningen, C. J.

AU - Van Der Vijgh, W. J F

AU - Postmus, P. E.

AU - Pinedo, H. M.

AU - Peters, G. J.

PY - 2006/10

Y1 - 2006/10

N2 - Purpose: To compare the pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer (NSCLC). Patients and methods: Twenty-four chemo-naive patients with advanced NSCLC were randomized to receive one of the three regimens. Plasma pharmacokinetics and pharmacologic parameters in mononuclear cells were compared and related to toxicity and efficacy. Results: Pharmacological parameters of gemcitabine and cisplatin were not influenced by the combination with one of the other agents, while the paclitaxel clearance was significantly lower for the combination with cisplatin as compared to gemcitabine (P=0.024). The percentage decrease in platelets was significantly higher for the gemcitabine combinations (P=0.004) and related to the dFdCTP-Cmax (P=0.030). Pharmacologic parameters were not related to response or survival. Conclusions: Gemcitabine and cisplatin pharmacology were not influenced by the combination with one of the other agents, while paclitaxel has a lower clearance in combination with cisplatin as compared to gemcitabine.

AB - Purpose: To compare the pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer (NSCLC). Patients and methods: Twenty-four chemo-naive patients with advanced NSCLC were randomized to receive one of the three regimens. Plasma pharmacokinetics and pharmacologic parameters in mononuclear cells were compared and related to toxicity and efficacy. Results: Pharmacological parameters of gemcitabine and cisplatin were not influenced by the combination with one of the other agents, while the paclitaxel clearance was significantly lower for the combination with cisplatin as compared to gemcitabine (P=0.024). The percentage decrease in platelets was significantly higher for the gemcitabine combinations (P=0.004) and related to the dFdCTP-Cmax (P=0.030). Pharmacologic parameters were not related to response or survival. Conclusions: Gemcitabine and cisplatin pharmacology were not influenced by the combination with one of the other agents, while paclitaxel has a lower clearance in combination with cisplatin as compared to gemcitabine.

KW - Cisplatin

KW - Gemcitabine

KW - Non-small cell lung cancer

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=33745726210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745726210&partnerID=8YFLogxK

U2 - 10.1007/s00280-006-0191-z

DO - 10.1007/s00280-006-0191-z

M3 - Article

C2 - 16523337

AN - SCOPUS:33745726210

SN - 0344-5704

VL - 58

SP - 509

EP - 516

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 4

ER -

Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this